Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8537448 | Progress in Neuro-Psychopharmacology and Biological Psychiatry | 2018 | 38 Pages |
Abstract
Placebo response in rTMS depression trials was large and associated with depression improvement of the active treatment group. Such result suggests that excluding placebo responders with a run-in phase may not confer advantage since response to 'active' rTMS may decrease as well. Moreover, placebo response may be a component of therapeutic response to rTMS in MDD. In addition, placebo response increase over time could indicate improvement in rTMS trial designs, including better sham rTMS methods.
Keywords
Related Topics
Life Sciences
Neuroscience
Biological Psychiatry
Authors
LaÃs B. Razza, Adriano H. Moffa, Marina L. Moreno, Andre F. Carvalho, Frank Padberg, Felipe Fregni, André R. Brunoni,